Flechtner Jessica Baker
Chief Scientific Officer at GENOCEA BIOSCIENCES, INC.
- Sold, on record
- $314k
- Dollars the filings state
- Form 4 sales
- 13
- Latest Jun 2, 2022
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- GENOCEA BIOSCIENCES, INC.Chief Scientific Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale GENOCEA BIOSCIENCES, INC.UnusualJun 1, 2015 2015
Sold 2,229 shares at $10.52 ($23k)
Flechtner Jessica Baker, Sr. VP of Research
Sold 54.2% of holdings ($43k position)1,881 shares left0.6x usual sizeFiling
- 2 Form 4 sale GENOCEA BIOSCIENCES, INC.UnusualJul 1, 2015 +30 days
Sold 2,229 shares at $13.92 ($31k)
Flechtner Jessica Baker, Sr. VP of Research
Sold 54.2% of holdings ($57k position)1,881 shares left0.7x usual sizeFiling
- 3 Form 4 sale GENOCEA BIOSCIENCES, INC.UnusualAug 3, 2015 +33 days
Sold 2,229 shares at $13.05 ($29k)
Flechtner Jessica Baker, Sr. VP of Research
Sold 54.2% of holdings ($54k position)1,881 shares left1x usual sizeFiling
- 4 Form 4 sale GENOCEA BIOSCIENCES, INC.UnusualSep 1, 2015 +29 days
Sold 2,229 shares at $11.35 ($25k)
Flechtner Jessica Baker, Sr. VP of Research
Sold 54.2% of holdings ($47k position)1,881 shares left1x usual sizeFiling
- 5 Form 4 sale GENOCEA BIOSCIENCES, INC.Plan not statedMar 16, 2022 +2388 days
Sold 3,349 shares at $1.10 ($4k)
Flechtner Jessica Baker, Chief Scientific Officer
Sold 3.3% of holdings ($111k position)97,405 shares leftFirst sale on recordFiling
- 6 Form 4 sale GENOCEA BIOSCIENCES, INC.Plan not statedApr 4, 2022 +19 days
Sold 1,212 shares at $1.25 ($2k)
Flechtner Jessica Baker, Chief Scientific Officer
Sold 1.2% of holdings ($122k position)96,193 shares leftFiling
- 7 Form 4 sale GENOCEA BIOSCIENCES, INC.Plan not statedMay 25, 2022 +51 days
Sold 16,525 shares at $0.0900 ($1k)
Flechtner Jessica Baker, Chief Scientific Officer
Sold 15.4% of holdings ($10k position)90,605 shares leftFiling
- 8 Form 4 sale GENOCEA BIOSCIENCES, INC.Plan not statedJun 2, 2022 +8 days
Sold 1,578 shares at $0.0600 ($95)
Flechtner Jessica Baker, Chief Scientific Officer
Sold 1.7% of holdings ($5k position)89,027 shares left0.5x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (13)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2022 | Jun 3, 2022 | GENOCEA BIOSCIENCES, INC. | Chief Scientific Officer | Form 4 sale | 1,578 | $95 | 1.7% | Plan not stated | SEC |
| May 25, 2022 | May 26, 2022 | GENOCEA BIOSCIENCES, INC. | Chief Scientific Officer | Form 4 sale | 16,525 | $1k | 15.4% | Plan not stated | SEC |
| Apr 4, 2022 | Apr 5, 2022 | GENOCEA BIOSCIENCES, INC. | Chief Scientific Officer | Form 4 sale | 1,212 | $2k | 1.2% | Plan not stated | SEC |
| Mar 16, 2022 | Mar 17, 2022 | GENOCEA BIOSCIENCES, INC. | Chief Scientific Officer | Form 4 sale | 3,349 | $4k | 3.3% | Plan not stated | SEC |
| Sep 1, 2015 | Sep 3, 2015 | GENOCEA BIOSCIENCES, INC. | Sr. VP of Research | Form 4 sale | 2,229 | $25k | 54.2% | Unusual | SEC |
| Aug 3, 2015 | Aug 5, 2015 | GENOCEA BIOSCIENCES, INC. | Sr. VP of Research | Form 4 sale | 2,229 | $29k | 54.2% | Unusual | SEC |
| Jul 1, 2015 | Jul 6, 2015 | GENOCEA BIOSCIENCES, INC. | Sr. VP of Research | Form 4 sale | 2,229 | $31k | 54.2% | Unusual | SEC |
| Jun 1, 2015 | Jun 2, 2015 | GENOCEA BIOSCIENCES, INC. | Sr. VP of Research | Form 4 sale | 2,229 | $23k | 54.2% | Unusual | SEC |
| May 1, 2015 | May 4, 2015 | GENOCEA BIOSCIENCES, INC. | Sr. VP of Research | Form 4 sale | 2,229 | $23k | 54.2% | Unusual | SEC |
| Apr 1, 2015 | Apr 3, 2015 | GENOCEA BIOSCIENCES, INC. | Sr. VP of Research | Form 4 sale | 2,283 | $27k | 54.8% | Unusual | SEC |
| Mar 2, 2015 | Mar 4, 2015 | GENOCEA BIOSCIENCES, INC. | Sr. VP of Research | Form 4 sale | 3,754 | $32k | 66.6% | Unusual | SEC |
| Feb 2, 2015 | Feb 2, 2015 | GENOCEA BIOSCIENCES, INC. | Sr. VP of Research | Form 4 sale | 4,699 | $40k | 71.4% | Unusual | SEC |
| Sep 12, 2014 | Sep 15, 2014 | GENOCEA BIOSCIENCES, INC. | VP of Research | Form 4 sale | 6,435 | $77k | 79.3% | Unusual | SEC |